Ponatinib for CML patients in routine clinical practice: the PONDEROSA study

Abstract Ponatinib, a third-generation tyrosine kinase inhibitor, is effective in patients with chronic myeloid leukemia (CML), particularly in cases of resistance or BCR::ABL1 T315I mutation. However, arterial occlusive events (AOEs) remain an important safety concern. The PONDEROSA registry evalua...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Thomas Schenk, Christian Fabisch, Thomas Ernst, Philipp Ernst, Susanne Saussele, Daniela Žáčková, Jiří Mayer, Hana Klamová, Andreas Hochhaus, for the German CML Study Group and the Czech Leukemia Study Group
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Springer 2026-01-01
Edice:	Annals of Hematology
Témata:	Chronic myeloid leukemia Ponatinib Registry Real-world evidence Dose optimization Arterial occlusive events
On-line přístup:	https://doi.org/10.1007/s00277-026-06788-6
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!